8-K: Zai Lab Q3 2025 Revenue Jumps 14%, Operating Loss Narrows

Zai Lab Limited reported a 14% year-over-year revenue increase to $116.1 million in Q3 2025, alongside a 28% improvement in operating loss, and revised full-year revenue guidance to at least $460 million.

Summary

• Total revenues grew 14% year-over-year to $116.1 million in the third quarter of 2025.
• Operating loss improved by 28% year-over-year to $48.8 million, and by 42% to $28.0 million on an adjusted basis.
• Net loss decreased to $36.0 million in Q3 2025, compared to $41.7 million for the same period in 2024.
• Revised total revenue guidance for the full year 2025 to at least $460 million.
• Initiated a global registrational study for zocilurtatug pelitecan (zoci, DLL3 ADC) monotherapy in second-line+ extensive-stage small cell lung cancer (ES-SCLC).
• Updated Phase 1 results for zoci demonstrated a best overall response rate of 68% at the 1.6 mg/kg dose in 2L ES-SCLC, with an estimated median duration of response (DoR) of 6.1 months.
• KarXT was included for the first time in China's national-level treatment guidelines for schizophrenia, underscoring the urgent need for novel therapies.
• The U.S. FDA granted Breakthrough Therapy Designation and a rolling review for povetacicept for the treatment of IgA nephropathy (IgAN).
• Cash and cash equivalents, short-term investments, and current restricted cash totaled $817.2 million as of September 30, 2025.

Sentiment

Score: 8

Explanation: The filing indicates strong financial performance with significant revenue growth and improved profitability, coupled with substantial progress in the global pipeline, including the initiation of a registrational study for a key oncology asset and Breakthrough Therapy Designation for an immunology asset. While there are some competitive pressures on ZEJULA and a study termination for bemarituzumab, the overall outlook and operational execution appear very positive.

Positives

• Total revenues increased 14% year-over-year to $116.1 million in the third quarter of 2025.
• Operating loss improved significantly by 28% year-over-year to $48.8 million (42% on an adjusted basis to $28.0 million).
• Net loss decreased to $36.0 million in Q3 2025 from $41.7 million in Q3 2024, primarily due to increased product revenue and decreased operating expenses.
• Full-year 2025 total revenue guidance was revised to at least $460 million, indicating confidence in future performance.
• Initiation of a global registrational study for zocilurtatug pelitecan (zoci, DLL3 ADC) in second-line+ extensive-stage small cell lung cancer (ES-SCLC), less than two years after IND.
• Strong Phase 1 results for zoci, demonstrating a 68% overall response rate at the 1.6 mg/kg dose in 2L ES-SCLC and meaningful activity (80% response rate) in patients with untreated brain metastases.
• KarXT's inclusion in China's national-level treatment guidelines for schizophrenia, highlighting its broad efficacy across all three symptom domains and unique safety profile.
• The U.S. FDA granted Breakthrough Therapy Designation and rolling review for povetacicept for IgA nephropathy (IgAN), accelerating its development path.
• VYVGART and VYVGART Hytrulo sales grew 4.6% quarter-over-quarter, driven by an extension of duration of therapy and increased market penetration.
• NUZYRA sales grew significantly to $15.4 million in Q3 2025 from $10.0 million in Q3 2024, supported by increased market coverage and penetration.
• XACDURO, launched in Q4 2024, generated $6.4 million in Q3 2025.
• Research and Development (R&D) expenses decreased to $47.9 million in Q3 2025 from $66.0 million in Q3 2024, primarily due to a decrease in licensing fees.
• The company maintains a strong cash position with $817.2 million in cash and cash equivalents, short-term investments, and current restricted cash as of September 30, 2025.

Negatives

• ZEJULA sales were softer at $42.4 million in Q3 2025, down from $48.2 million for the same period in 2024, due to evolving competitive dynamics within the PARPi class.
• The Phase 1b/3 FORTITUDE-102 study of bemarituzumab plus chemotherapy and nivolumab in first-line gastric cancer was stopped.
• VYVGART and VYVGART Hytrulo sales included a $2.4 million reduction following a voluntary price adjustment on Hytrulo ahead of National Reimbursement Drug List (NRDL) negotiation.

Risks

• Evolving competitive dynamics within the PARPi class impacting ZEJULA sales.
• Inherent risks associated with drug development and commercialization, including clinical trial outcomes and regulatory approvals, as evidenced by the stopping of the bemarituzumab study.
• Potential for future price adjustments or competitive pressures on commercialized products.

Future Outlook

Zai Lab anticipates advancing several global pipeline programs, including presenting updated data for zocilurtatug pelitecan (zoci) in H1 2026, initiating a registrational study for zoci in 2026, and submitting an IND for ZL-6201 by year-end 2025. The company also expects NMPA submissions for Tumor Treating Fields (TTFields) and efgartigimod in Q4 2025, and potential NMPA approvals for KarXT, Tisotumab Vedotin, and Repotrectinib. Full-year 2025 total revenue guidance has been revised to at least $460 million, reflecting continued growth expectations.

Management Comments

• "Zai Lab is entering the next phase of our growth, powered by the rapid advancement of our global pipeline and supported by a commercially profitable and scalable business in China." Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab.
• "With zoci moving into pivotal development less than two years after IND and multiple differentiated global programs progressing in parallel, we are demonstrating the speed, scientific rigor, and global ambition of our R&D engine." Dr. Samantha Du.
• "Our commercial platform in China remains strong, with new products and indications including KarXT, povetacicept and VYVGART broadening our long-term growth profile." Dr. Samantha Du.
• "This quarter, we continued to deepen the foundations of the VYVGART launch. In gMG, we are seeing steady new patient starts and increasing treatment duration, supported by updated treatment guidelines and real-world experience." Josh Smiley, President and COO of Zai Lab.
• "Physician confidence continues to grow and reinforces the long-term potential of VYVGART as a new standard of care in the treatment of this chronic disease." Josh Smiley.
• "Looking ahead, we are preparing for our next expected launch for KarXT in schizophrenia. We remain focused on disciplined execution as we position for the significant opportunities ahead, supported by a growing regional business and a rapidly progressing, global pipeline." Josh Smiley.

Industry Context

The biopharmaceutical industry continues to prioritize innovation in oncology, immunology, and neuroscience, areas where Zai Lab is actively developing its pipeline. The advancement of novel antibody-drug conjugates (ADCs) like zocilurtatug pelitecan for ES-SCLC and bispecific antibodies like ZL-1503 for atopic dermatitis aligns with the industry's shift towards targeted and differentiated therapies. KarXT's inclusion in China's national treatment guidelines for schizophrenia highlights the significant unmet need for novel neuroscience treatments globally, positioning Zai Lab favorably in a major market. The competitive dynamics observed in the PARPi class, impacting ZEJULA sales, underscore the intense competition and rapid evolution within established therapeutic areas.

Comparison to Industry Standards

• The 68% overall response rate for zocilurtatug pelitecan (zoci) at 1.6 mg/kg in second-line extensive-stage small cell lung cancer (ES-SCLC) and an estimated median duration of response (DoR) of 6.1 months are highly encouraging for a monotherapy in this heavily pre-treated and difficult-to-treat patient population, potentially positioning it as a best-in-class candidate compared to existing therapies which often show lower response rates and shorter DoRs in this setting.
• The 80% response rate for zoci in patients with untreated brain metastases is particularly notable, as brain metastases are a significant challenge in ES-SCLC, and therapies demonstrating meaningful activity in this subgroup are highly valued and often represent a significant advantage over standard treatments.
• The inclusion of KarXT in China's national-level treatment guidelines for schizophrenia, emphasizing its broad efficacy across positive, negative, and cognitive symptoms and unique safety profile, suggests a potential advantage over many current antipsychotics that may have limited efficacy across all symptom domains or significant side effects impacting long-term adherence.
• The FDA's Breakthrough Therapy Designation and rolling review for povetacicept in IgA nephropathy (IgAN) indicates that the agency recognizes its potential to offer substantial improvement over available therapies for a serious condition, aligning it with other rapidly advancing treatments for rare kidney diseases that receive expedited regulatory pathways.
• The stopping of the FORTITUDE-102 study for bemarituzumab, while a setback, is a common occurrence in pharmaceutical R&D, reflecting the high-risk nature of drug development where many investigational therapies fail to meet efficacy or safety endpoints, a reality faced by companies across the industry.

Stakeholder Impact

• Shareholders: Positive financial results, improved operating loss, and strong pipeline advancements could lead to increased shareholder value. The revised full-year revenue guidance provides clearer expectations for future performance.
• Patients: Advancement of multiple drug candidates (zoci, KarXT, povetacicept, ZL-1503) addresses significant unmet medical needs in oncology, neuroscience, and immunology, potentially offering new and improved treatment options.
• Employees: Continued growth and pipeline expansion suggest a stable and potentially growing work environment, with ongoing opportunities in R&D and commercialization.
• Customers (Healthcare Providers): New product launches and guideline inclusions (KarXT) provide more treatment options and support for patient care, enhancing the company's offering to the medical community.
• Partners: Continued collaboration and successful clinical development (e.g., argenx, Vertex) strengthen existing partnerships and may attract new collaborations, fostering mutual growth.

Next Steps

• Present updated data on intracranial activity for zocilurtatug pelitecan (zoci) from the ongoing Phase 1 study in the first half of 2026.
• Provide data readout from the Phase 1 study evaluating zoci combination therapy (with atezolizumab and/or chemotherapy) in the first half of 2026 and advance into a registrational study in 2026.
• Initiate a Phase 1 study to explore zoci in a novel combination in 2026.
• Provide data readout from the global Phase 1/2 study of zoci in other neuroendocrine carcinomas in the first half of 2026 and advance into a registrational-enabling cohort in 2026.
• Provide the initial data readout from the global Phase 1/1b study for ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis in 2026.
• Submit an Investigational New Drug application (IND) to the FDA for a global Phase 1 study for ZL-6201 (LRRC15 ADC) in the fourth quarter of 2025.
• Submit for NMPA regulatory approval for Tumor Treating Fields (TTFields) in first-line pancreatic cancer in the fourth quarter of 2025.
• Submit for NMPA regulatory approval for efgartigimod (FcRn) for prefilled syringe in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) in the fourth quarter of 2025.
• Prepare for the launch of KarXT in schizophrenia following its inclusion in China's national-level treatment guidelines.
• Await NMPA approvals for KarXT in schizophrenia, Tisotumab Vedotin in recurrent or metastatic cervical cancer, and Repotrectinib in NTRK+ solid tumors.
• Join the global pivotal Phase 2/3 OLYMPUS study of povetacicept in primary membranous nephropathy (pMN) in Greater China in the fourth quarter of 2025.
• Vertex to submit the first module of the IgAN Biologics License Application (BLA) to the FDA before the end of 2025 and complete the full BLA submission in the first half of 2026 for potential accelerated approval in the U.S.
• Initiate a registrational study for VRDN-003 in Thyroid Eye Disease (TED) in Greater China in the fourth quarter of 2025.
• Await topline results from global registrational REVEAL-1 study in active TED patients in the first quarter of 2026 and global registrational REVEAL-2 study in chronic TED in the second quarter of 2026 for VRDN-003.
• Await topline results from the global Phase 3 ADAPT-OCULUS study for efgartigimod in ocular myasthenia gravis in the first half of 2026.
• Await topline results from the global Phase 2/3 ALKIVIA study for efgartigimod evaluating three myositis subsets in the second half of 2026.
• Await topline results from two registrational UplighTED studies for efgartigimod in Thyroid Eye Disease (TED) in the second half of 2026.

Key Dates

Recommendation

The filing demonstrates robust financial health with significant year-over-year revenue growth and a substantial reduction in operating loss, indicating improved operational efficiency and a clear path towards profitability. The upward revision of full-year revenue guidance further reinforces a positive financial trajectory. Critically, the company's pipeline is advancing rapidly with high-potential assets: zocilurtatug pelitecan (zoci) has shown compelling Phase 1 data and is moving into a global registrational study, KarXT has achieved national guideline inclusion in China, and povetacicept received Breakthrough Therapy Designation and rolling review from the FDA. These clinical and regulatory milestones de-risk future revenue streams and highlight strong R&D execution. While there are minor setbacks like ZEJULA's competitive pressures and a terminated partner study, the overall strategic direction, commercial execution in China, and global pipeline progress present a highly attractive investment opportunity for long-term growth.

Keywords

Zai Lab, ZLAB, 9688, Biopharmaceutical, Oncology, Immunology, Neuroscience, Infectious Disease, Financial Results, Q3 2025, Revenue, Operating Loss, Pipeline, Zocilurtatug Pelitecan, zoci, DLL3 ADC, ES-SCLC, KarXT, Schizophrenia, Povetacicept, IgA Nephropathy, VYVGART, ZEJULA, XACDURO, NUZYRA, SEC Filing, 8-K